Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
Related Tickers: APRE
TL;DR
APRE filed an 8-K on 10/24/25, but it's light on details for now.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on October 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only that they are being reported.
Why It Matters
This filing indicates that Aprea Therapeutics has made a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or negative events.
Key Numbers
- 001-39069 — Commission File Number (Identifies the company's SEC filing history.)
- 84-2246769 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- October 24, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 215-948-4119 (phone_number) — Business Phone
FAQ
What specific 'Other Events' are being reported by Aprea Therapeutics, Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as an item information.
What is the significance of the 'Financial Statements and Exhibits' being reported?
The filing indicates that financial statements and exhibits are part of this report, but their specific content is not detailed within the provided text.
When was this 8-K filing submitted to the SEC?
The filing was submitted on October 24, 2025.
What is Aprea Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is the company's state of incorporation?
Aprea Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-10-24 08:35:24
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
Filing Documents
- apre-20251024x8k.htm (8-K) — 38KB
- apre-20251024xex99d1.htm (EX-99.1) — 27KB
- apre-20251024xex99d1001.jpg (GRAPHIC) — 5KB
- apre-20251024xex99d1002.jpg (GRAPHIC) — 4KB
- 0001104659-25-102004.txt ( ) — 198KB
- apre-20251024.xsd (EX-101.SCH) — 3KB
- apre-20251024_def.xml (EX-101.DEF) — 3KB
- apre-20251024_lab.xml (EX-101.LAB) — 16KB
- apre-20251024_pre.xml (EX-101.PRE) — 11KB
- apre-20251024x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On October 24, 2025, Aprea Therapeutics, Inc. issued a press release providing a clinical update from the ACESOT-1051 trial showing early signals of activity for WEE1 Kinase Inhibitor APR-1051. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated October 24, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: October 24, 2025 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer